WO1997029128A1 - COMPLEXE GPIb-LIPIDE ET SES UTILISATIONS - Google Patents

COMPLEXE GPIb-LIPIDE ET SES UTILISATIONS Download PDF

Info

Publication number
WO1997029128A1
WO1997029128A1 PCT/JP1997/000284 JP9700284W WO9729128A1 WO 1997029128 A1 WO1997029128 A1 WO 1997029128A1 JP 9700284 W JP9700284 W JP 9700284W WO 9729128 A1 WO9729128 A1 WO 9729128A1
Authority
WO
WIPO (PCT)
Prior art keywords
vascular
parts
gpib
useful
vwf
Prior art date
Application number
PCT/JP1997/000284
Other languages
English (en)
French (fr)
Inventor
Hiroshi Matsuda
Kaeko Kamide
Yasuo Amatsuji
Takashi Imagawa
Yasuo Ikeda
Mitsuru Murata
Original Assignee
The Green Cross Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Green Cross Corporation filed Critical The Green Cross Corporation
Priority to EP97902589A priority Critical patent/EP0894807A4/en
Priority to US09/117,746 priority patent/US6177059B1/en
Publication of WO1997029128A1 publication Critical patent/WO1997029128A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/JP1997/000284 1996-02-07 1997-02-06 COMPLEXE GPIb-LIPIDE ET SES UTILISATIONS WO1997029128A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP97902589A EP0894807A4 (en) 1996-02-07 1997-02-06 GPIb lipid complex and its applications
US09/117,746 US6177059B1 (en) 1996-02-07 1997-02-06 GPIb-lipid complex and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8/21482 1996-02-07
JP02148296A JP3735921B2 (ja) 1996-02-07 1996-02-07 ＧＰＩｂ・脂質複合体およびその用途

Publications (1)

Publication Number Publication Date
WO1997029128A1 true WO1997029128A1 (fr) 1997-08-14

Family

ID=12056200

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1997/000284 WO1997029128A1 (fr) 1996-02-07 1997-02-06 COMPLEXE GPIb-LIPIDE ET SES UTILISATIONS

Country Status (4)

Country Link
US (1) US6177059B1 (ja)
EP (1) EP0894807A4 (ja)
JP (1) JP3735921B2 (ja)
WO (1) WO1997029128A1 (ja)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064743A1 (fr) * 2000-03-02 2001-09-07 Mitsubishi Pharma Corporation CONSTRUCTION A LIAISON GPib-LIPIDE ET UTILISATION CORRESPONDANTE
US20040057988A1 (en) * 2000-11-10 2004-03-25 Eishun Tsuchida Method for preparing microsome dispersion
AR035779A1 (es) * 2001-02-06 2004-07-14 Genetics Inst Llc Polipeptidos de fusion derivados de glicoproteina ib alfa de plaqueta y metodos de uso de los mismos
NZ518163A (en) * 2002-04-05 2005-04-29 Kiwi Ingenuity Ltd Embryo modified with a glycolipid to enhance implantation into the endometrium
US20070059376A1 (en) * 2003-02-06 2007-03-15 Shinji Takeoka Peptide conjugate
WO2004075925A1 (ja) * 2003-02-27 2004-09-10 Kyushu Tlo Company Limited Ｍｒｉ用造影剤
JP2007537710A (ja) * 2003-06-11 2007-12-27 ワイス 血小板糖タンパク質ＩＢα改変体融合ポリペプチドおよびその使用法
AU2005206053A1 (en) * 2004-01-23 2005-08-04 Keio University Support accumulating in injured part in vascular channel
US8173595B2 (en) * 2004-05-04 2012-05-08 The Board Of Trustees Of The University Of Illinois Methods and compositions for the inhibition of thrombus formation
US20090181057A1 (en) * 2004-05-04 2009-07-16 The Board Of Trustees Of The University Of Illinois Methods and Compositions for the Inhibition of Thrombus Formation
BRPI0514984A (pt) 2004-09-07 2008-07-01 Archemix Corp aptámeros para o fator de von willebrand e sua utilização como terapêuticos para doença trombótica
WO2006029258A2 (en) * 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
JP5216219B2 (ja) * 2006-01-06 2013-06-19 真司 武岡 薬物運搬体
US7887837B2 (en) * 2006-01-06 2011-02-15 Shinji Takeoka Drug delivery material
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
KR20090029697A (ko) * 2006-04-07 2009-03-23 더 리전츠 오브 더 유니버시티 오브 캘리포니아 초임계 암모니아 내에서 넓은 표면적 질화 갈륨 결정을 성장시키는 방법 및 넓은 표면적 질화 갈륨 결정
US8357243B2 (en) * 2008-06-12 2013-01-22 Sixpoint Materials, Inc. Method for testing group III-nitride wafers and group III-nitride wafers with test data
US20100095882A1 (en) * 2008-10-16 2010-04-22 Tadao Hashimoto Reactor design for growing group iii nitride crystals and method of growing group iii nitride crystals
PL2007885T3 (pl) * 2006-04-11 2010-12-31 Csl Behring Gmbh Sposób zwiększania odzysku peptydów terapeutycznych in vivo
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
US20080015145A1 (en) * 2006-07-11 2008-01-17 Maria Gyongyossy-Issa Mimotope receptors and inhibitors for platelet-platelet and platelet-endothelium interactions
CA2600220C (en) * 2006-09-07 2014-12-09 Canadian Blood Services Surface cross-linked lipidic particles, methods of production and uses therefor
WO2008077616A1 (en) * 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
WO2009108700A1 (en) * 2008-02-25 2009-09-03 Sixpoint Materials, Inc. Method for producing group iii nitride wafers and group iii nitride wafers
WO2009149300A1 (en) 2008-06-04 2009-12-10 Sixpoint Materials High-pressure vessel for growing group iii nitride crystals and method of growing group iii nitride crystals using high-pressure vessel and group iii nitride crystal
EP2281076A1 (en) 2008-06-04 2011-02-09 Sixpoint Materials, Inc. Methods for producing improved crystallinty group iii-nitride crystals from initial group iii-nitride seed by ammonothermal growth
WO2009152445A1 (en) * 2008-06-13 2009-12-17 Marval Biosciences, Inc. Imaging of atherosclerotic plaques using liposomal imaging agents
KR20110097813A (ko) * 2008-11-07 2011-08-31 더 리전츠 오브 더 유니버시티 오브 캘리포니아 Ⅲ족 질화물 결정들의 암모노열 성장을 위한 신규한 용기 설계 및 소스 물질과 씨드 결정들의 상기 용기에 대한 상대적인 배치
WO2010060034A1 (en) * 2008-11-24 2010-05-27 Sixpoint Materials, Inc. METHODS FOR PRODUCING GaN NUTRIENT FOR AMMONOTHERMAL GROWTH
WO2010129718A2 (en) 2009-05-05 2010-11-11 Sixpoint Materials, Inc. Growth reactor for gallium-nitride crystals using ammonia and hydrogen chloride
CA2857604A1 (en) 2011-12-22 2013-06-27 Nuvo Research Gmbh Liposomal chlorite or chlorate compositions
MX2015000813A (es) 2012-07-18 2015-09-07 Onyx Therapeutics Inc Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
EP3285742A4 (en) * 2015-04-20 2018-11-21 Academia Sinica Platelet-like proteo-microparticles and method of using such in drug delivery
WO2018087720A1 (en) 2016-11-14 2018-05-17 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5123395B2 (ja) * 1972-10-23 1976-07-16
MX9203291A (es) * 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5428008A (en) * 1989-04-14 1995-06-27 Prp, Inc. Therapeutic composition of micellar structures capable of promoting hemotasis
ATE136211T1 (de) * 1989-06-23 1996-04-15 Liposome Co Inc Zielliposomen und verfahren zur kupplung von liposomen-proteinen
US5462752A (en) * 1994-07-28 1995-10-31 Prp, Inc. Inhibition of platelet binding

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP0894807A4 *
SIÈ P, ET AL: "Reconstitution of Liposomes Bearing Platelet Membrane Glycoproteins. A Func tional Study With Von Willebrand Factor", PROTIDES OF THE BIOLOGICAL FLUIDS., PERGAMON PRESS, OXFORD., GB, no. 29TH, 1 January 1981 (1981-01-01), GB, pages 79 - 83, XP002956056, ISSN: 0079-7065 *

Also Published As

Publication number Publication date
EP0894807A1 (en) 1999-02-03
JPH09208599A (ja) 1997-08-12
US6177059B1 (en) 2001-01-23
EP0894807A4 (en) 2001-12-05
JP3735921B2 (ja) 2006-01-18

Similar Documents

Publication Publication Date Title
WO1997029128A1 (fr) COMPLEXE GPIb-LIPIDE ET SES UTILISATIONS
CA2194369A1 (en) Methods and compositions for the specific coagulation of vasculature
CA2310850A1 (en) A covalent conjugate of clozapine with a fatty acid and its use for treating schizophrenia
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
SE8902377D0 (sv) Foerfarande foer framstaellning av ett vaevnadsbindemedel
PT637933E (pt) Metodo para tratamento de orgaos e tecidos
MX9603570A (es) Metodo y composiciones para incrementar la vida media en suero de agentes farmacologicamente activos.
DE3764253D1 (de) Medizinischer saugkoerper mit roentgenkontrastmittel und verfahren zu seiner herstellung.
HRP970450B1 (en) Phenyl-substituted alkenoylguanidides, process for their preparation, their use as drugs or diagnostic agents and drugs containing them
EP0996460A4 (en) TREATMENT OF FIBROSIS OR ACUTE PULMONARY DAMAGE USING ANTAGONISTS OF $ g (a) v $ g (b) 6
DE68913141D1 (de) Adhäsif für mehrschichtige Wegwerfartikel.
GB8628398D0 (en) Pharmaceutically-active conjugates
EP2108378A3 (en) Non-covalent bioconjugates useful for diagnosis and therapy
EE04046B1 (et) Vitamiini D ja kaltsiumit sisaldav ravimkoostis, selle valmistamine ja terapeutiline kasutamine
CA2070647A1 (en) Use of an anticoagulant as a diagnostic agent
WO1997045145A3 (en) A diagnostic test for schizophrenia, using niacin
PL309218A1 (en) Anticoagulant
HRP970292A2 (en) Substituted 2-naphtoylguanidines, process for their preparation, their use as medicament or diagnostic agent and medicament containing them
FR2720070B1 (fr) Procédé de préparation d'alkylpolysiloxanes pontés et alkylpolysiloxanes pontés.
AU2330095A (en) Ortho-amino-substituted benzoylguanidines, a process for their preparation, their use as a medicament or diagnostic agent, and also a medicament containing them
IL115652A (en) Use of vWF or fragments thereof for the preparation of medicaments having an antidote effect to antithrombotic and/or fibrinolytic agents producing hemorrhages
FI933507A (fi) Bisyklopolyatsamakrosyklofosfonihappoja, niiden komplekseja ja konjugaatteja käytettäväksi varjoaineina ja menetelmä niiden valmistamiseksi
HRP970294B1 (en) Substituted 1-naphtoylguanidines, process for their preparation, their use as medicament or diagnostic agent and medicaments containing them
HRP970293A2 (en) Bis-ortho-substituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic agent and medicaments containing them
IL114235A0 (en) Oligonucleotide conjugates and processes for noninvasive diagnosis utilizing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997902589

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09117746

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1997902589

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997902589

Country of ref document: EP